⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279341 | 0.95 | HPGD (0.50) | — | |
| SCHEMBL1595294 | 0.93 | HPGD (0.53) | — | |
| SCHEMBL209174 | 0.93 | HPGD (0.53) | — | |
| SCHEMBL745882 | 0.90 | — | — | |
| SCHEMBL21793689 | 0.84 | MAPT (0.42) | — | |
| SCHEMBL7729860 | 0.83 | HPGD (0.46) | — | |
| SCHEMBL8788705 | 0.81 | CYP1A2 (0.43) | — | |
| SCHEMBL25479677 | 0.79 | TSHR (0.42) | — | |
| SCHEMBL25181503 | 0.79 | TSHR (0.37) | — | |
| SCHEMBL10422799 | 0.79 | TSHR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092780-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | ANKH LIFE SCIENCES LIMITED (IE) | 2024-03-21 | — | — | US | disclosed |
| WO-2024050395-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | ANKH LIFE SCIENCES LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| CN-103389621-B | A kind of Oxime ester sulfonate type photo-acid generator | CHANGZHOU QIANGLI ADVANCED ELECTRIC MATERIALS CO., LTD. (CN) | 2016-03-16 | — | — | CN | disclosed |
| CN-103389621-A | Oxime ester sulfonate type photo-acid generator | CHANGZHOU TRONLY ADVANCED ELECTRONIC MATERIALS CO LTD | 2013-11-13 | — | — | CN | disclosed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
| US-7112583-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1212306-A2 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
| WO-2001019797-A2 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
| US-4108997-A | Diuretic [2]benzopyrano[4,3-b]pyridines and process therefor | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1978-08-22 | — | — | US | disclosed |